Correction: Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma (Oncogene, (2011), 30, 25, (2823-2835), 10.1038/onc.2011.10);Bone morphogenetic protein-7 is a MYC target with prosurvival functions in childhood medulloblastoma

Oncogene

Volumn 30, Issue 25, 2011, Pages 2823-2835

  Fiaschetti, G ^a   Castelletti, D ^a   Zoller, S ^b   Schramm, A ^c   Schroeder, C ^d   Nagaishi, M ^e   Stearns, D ^f   Mittelbronn, M ^g   Eggert, A ^c   Westermann, F ^d   Ohgaki, H ^e   Shalaby, T ^a   Pruschy, M ^h   Arcaro, A ⁱ   Grotzer, M A ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b FUNCTIONAL GENOMICS CENTER ZURICH   (Switzerland)

^c UNIVERSITY HOSPITAL ESSEN   (Germany)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^e INTERNATIONAL AGENCY FOR RESEARCH ON CANCER   (France)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g GOETHE UNIVERSITY   (Germany)

^h UNIVERSITY HOSPITAL ZURICH   (Switzerland)

ⁱ UNIVERSITY OF BERN   (Switzerland)

Author keywords

BMP7; brain tumor; medulloblastoma; MYC; pediatric cancer

Indexed keywords

BONE MORPHOGENETIC PROTEIN; COMPLEMENTARY DNA; OSTEOGENIC PROTEIN 1; SMAD PROTEIN; SMALL INTERFERING RNA;

ARTICLE; BMP SMAD PATHWAY; CELL PROLIFERATION; CELL SURVIVAL; CHILDHOOD CANCER; CONTROLLED STUDY; DNA MICROARRAY; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; IN VITRO STUDY; MEDULLOBLASTOMA; ONCOGENE MYC; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN PROCESSING; SIGNAL TRANSDUCTION;

EID: 79959663967     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/s41388-022-02555-9     Document Type: Erratum

References (73)

1. Adhikary S, Eilers M. (2005). Transcriptional regulation and transformation by Myc proteins. Nat Rev Mol Cell Biol 6: 635-645.
2. Alder J, Lee KJ, Jessell TM, Hatten ME. (1999). Generation of cerebellar granule neurons in vivo by transplantation of BMPtreated neural progenitor cells. Nat Neurosci 2: 535-540.
3. Aldosari N, Bigner SH, Burger PC, Becker L, Kepner JL, Friedman HS et al. (2002). MYCC and MYCN oncogene amplification in medulloblastoma. A fluorescence in situ hybridization study on paraffin sections from the Childrens Oncology Group. Arch Pathol Lab Med 126: 540-544.
4. Anderson GJ, Darshan D. (2008). Small-molecule dissection of BMP signaling. Nat Chem Biol 4: 15-16.
5. Arihiro K, Inai K. (2001). Expression of CD31, Met/hepatocyte growth factor receptor and bone morphogenetic protein in bone metastasis of osteosarcoma. Pathol Int 51: 100-106.
6. Balemans W, Van Hul W. (2002). Extracellular regulation of BMP signaling in vertebrates: a cocktail of modulators. Dev Biol 250: 231-250.
7. Behesti H, Marino S. (2009). Cerebellar granule cells: insights into proliferation, differentiation, and role in medulloblastoma pathogenesis. Int J Biochem Cell Biol 41: 435-445.
8. Blanco Calvo M, Bolos Fernandez V, Medina Villaamil V, Aparicio Gallego G, Diaz Prado S, Grande Pulido E. (2009). Biology of BMP signalling and cancer. Clin Transl Oncol 11: 126-137.
9. Buijs JT, Henriquez NV, van Overveld PG, van der Horst G, Que I, Schwaninger R et al. (2007a). Bone morphogenetic protein 7 in the development and treatment of bone metastases from breast cancer. Cancer Res 67: 8742-8751.
10. Buijs JT, Petersen M, van der Horst G, van der Pluijm G. (2010). Bone morphogenetic proteins and its receptors; therapeutic targets in cancer progression and bone metastasis? Curr Pharm Des 16: 1291-1300.
11. Buijs JT, Rentsch CA, van der Horst G, van Overveld PG, Wetterwald A, Schwaninger R et al. (2007b). BMP7, a putative regulator of epithelial homeostasis in the human prostate, is a potent inhibitor of prostate cancer bone metastasis in vivo. Am J Pathol 171: 1047-1057.
12. Chen JK, Taipale J, Cooper MK, Beachy PA. (2002). Inhibition of Hedgehog signaling by direct binding of cyclopamine to smoothened. Genes Dev 16: 2743-2748.
13. Chizhikov VV, Lindgren AG, Currle DS, Rose MF, Monuki ES, Millen KJ. (2006). The roof plate regulates cerebellar cell-type specification and proliferation. Development 133: 2793-2804.
14. Crawford JR, MacDonald TJ, Packer RJ. (2007). Medulloblastoma in childhood: new biological advances. Lancet Neurol 6: 1073-1085.
15. Dai J, Hall CL, Escara-Wilke J, Mizokami A, Keller JM, Keller ET. (2008). Prostate cancer induces bone metastasis through Wntinduced bone morphogenetic protein-dependent and independent mechanisms. Cancer Res 68: 5785-5794.
16. Derynck R, Akhurst RJ, Balmain A. (2001). TGF-beta signaling in tumor suppression and cancer progression. Nat Genet 29: 117-129.
17. Dziegielewska KM, Ek J, Habgood MD, Saunders NR. (2001). Development of the choroid plexus. Microsc Res Tech 52: 5-20.
18. Eberhart CG, Kepner JL, Goldthwaite PT, Kun LE, Duffner PK, Friedman HS et al. (2002). Histopathologic grading of medulloblastomas: a Pediatric Oncology Group study. Cancer 94: 552-560.
19. Edgar R, Domrachev M, Lash AE. (2002). Gene expression omnibus: NCBI gene expression and hybridization array data repository. Nucleic Acids Res 30: 207-210.
20. Engelhard HH, Corsten LA. (2005). Leptomeningeal metastasis of primary central nervous system (CNS) neoplasms. Cancer Treat Res 125: 71-85.
21. Feeley BT, Gamradt SC, Hsu WK, Liu N, Krenek L, Robbins P et al. (2005). Influence of BMPs on the formation of osteoblastic lesions in metastatic prostate cancer. J Bone Miner Res 20: 2189-2199.
22. Fernandez PC, Frank SR, Wang L, Schroeder M, Liu S, Greene J et al. (2003). Genomic targets of the human c-Myc protein. Genes Dev 17: 1115-1129.
23. Filmus J, Capurro M, Rast J. (2008). Glypicans. Genome Biol 9: 224.
24. Gilbertson RJ, Ellison DW. (2008). The origins of medulloblastoma subtypes. Annu Rev Pathol 3: 341-365.
25. Grandori C, Cowley SM, James LP, Eisenman RN. (2000). The Myc/ Max/Mad network and the transcriptional control of cell behavior. Annu Rev Cell Dev Biol 16: 653-699.
26. Grimmer MR, Weiss WA. (2008). BMPs oppose Math1 in cerebellar development and in medulloblastoma. Genes Dev 22: 693-699.
27. Grisaru S, Cano-Gauci D, Tee J, Filmus J, Rosenblum ND. (2001). Glypican-3 modulates BMP- and FGF-mediated effects during renal branching morphogenesis. Dev Biol 231: 31-46.
28. Grotzer MA, Castelletti D, Fiaschetti G, Shalaby T, Arcaro A. (2009). Targeting Myc in pediatric malignancies of the central and peripheral nervous system. Curr Cancer Drug Targets 9: 176-188.
29. Guessous F, Li Y, Abounader R. (2008). Signaling pathways in medulloblastoma. J Cell Physiol 217: 577-583.
30. Guhaniyogi J, Brewer G. (2001). Regulation of mRNA stability in mammalian cells. Gene 265: 11-23.
31. Guo X, Wang XF. (2009). Signaling cross-talk between TGF-beta/ BMP and other pathways. Cell Res 19: 71-88.
32. Gurney JG, Kadan-Lottick N. (2001). Brain and other central nervous system tumors: rates, trends, and epidemiology. Curr Opin Oncol 13: 160-166.
33. Herms J, Neidt I, Luscher B, Sommer A, Schurmann P, Schroder T et al. (2000). C-MYC expression in medulloblastoma and its prognostic value. Int J Cancer 89: 395-402.
34. Iantosca MR, McPherson CE, Ho SY, Maxwell GD. (1999). Bone morphogenetic proteins-2 and -4 attenuate apoptosis in a cerebellar primitive neuroectodermal tumor cell line. J Neurosci Res 56: 248-258.
35. Irizarry RA, Bolstad BM, Collin F, Cope LM, Hobbs B, Speed TP. (2003). Summaries of Affymetrix GeneChip probe level data. Nucleic Acids Res 31: e15.
36. Krizhanovsky V, Ben-Arie N. (2006). A novel role for the choroid plexus in BMP-mediated inhibition of differentiation of cerebellar neural progenitors. Mech Dev 123: 67-75.
37. Kunz F, Shalaby T, Lang D, von Buren A, Hainfellner JA, Slavc I et al. (2006). Quantitative mRNA expression analysis of neurotrophin- receptor TrkC and oncogene c-MYC from formalin-fixed, paraffin-embedded primitive neuroectodermal tumor samples. Neuropathology 26: 393-399.
38. Lamont JM, McManamy CS, Pearson AD, Clifford SC, Ellison DW. (2004). Combined histopathological and molecular cytogenetic stratification of medulloblastoma patients. Clin Cancer Res 10: 5482-5493.
39. Langenfeld EM, Calvano SE, Abou-Nukta F, Lowry SF, Amenta P, Langenfeld J. (2003). The mature bone morphogenetic protein-2 is aberrantly expressed in non-small cell lung carcinomas and stimulates tumor growth of A549 cells. Carcinogenesis 24: 1445-1454.
40. Littlewood TD, Evan GI. (1990). The role of myc oncogenes in cell growth and differentiation. Adv Dent Res 4: 69-79.
41. Luo J, Chen J, Deng ZL, Luo X, Song WX, Sharff KA et al. (2007). Wnt signaling and human diseases: what are the therapeutic implications? Lab Invest 87: 97-103.
42. Ma L, Young J, Prabhala H, Pan E, Mestdagh P, Muth D et al. (2010). miR-9, a MYC/MYCN-activated microRNA, regulates E-cadherin and cancer metastasis. Nat Cell Biol 12: 247-256.
43. Marino S. (2005). Medulloblastoma: developmental mechanisms out of control. Trends Mol Med 11: 17-22.
44. Miyazaki H, Watabe T, Kitamura T, Miyazono K. (2004). BMP signals inhibit proliferation and in vivo tumor growth of androgeninsensitive prostate carcinoma cells. Oncogene 23: 9326-9335.
45. Miyazono K. (1999). Signal transduction by bone morphogenetic protein receptors: functional roles of Smad proteins. Bone 25: 91-93.
46. Miyazono K, Kamiya Y, Morikawa M. (2010). Bone morphogenetic protein receptors and signal transduction. J Biochem 147: 35-51.
47. Miyazono K, Maeda S, Imamura T. (2005). BMP receptor signaling: transcriptional targets, regulation of signals, and signaling crosstalk. Cytokine Growth Factor Rev 16: 251-263.
48. Mulhern RK, Palmer SL, Merchant TE, Wallace D, Kocak M, Brouwers P et al. (2005). Neurocognitive consequences of riskadapted therapy for childhood medulloblastoma. J Clin Oncol 23: 5511-5519.
49. Neben K, Korshunov A, Benner A, Wrobel G, Hahn M, Kokocinski F et al. (2004). Microarray-based screening for molecular markers in medulloblastoma revealed STK15 as independent predictor for survival. Cancer Res 64: 3103-3111.
50. Piccirillo SG, Vescovi AL. (2006). Bone morphogenetic proteins regulate tumorigenicity in human glioblastoma stem cells. Ernst Schering Found Symp Proc 5: 59-81.
51. Polkinghorn WR, Tarbell NJ. (2007).Medulloblastoma: tumorigenesis, current clinical paradigm, and efforts to improve risk stratification. Nat Clin Pract Oncol 4: 295-304.
52. Raida M, Clement JH, Ameri K, Han C, Leek RD, Harris AL. (2005). Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death. Int J Oncol 26: 1465-1470.
53. Redzic ZB, Segal MB. (2004). The structure of the choroid plexus and the physiology of the choroid plexus epithelium. Adv Drug Deliv Rev 56: 1695-1716.
54. Romer J, Curran T. (2005). Targeting medulloblastoma: smallmolecule inhibitors of the Sonic Hedgehog pathway as potential cancer therapeutics. Cancer Res 65: 4975-4978.
55. Rossi A, Caracciolo V, Russo G, Reiss K, Giordano A. (2008). Medulloblastoma: from molecular pathology to therapy. Clin Cancer Res 14: 971-976.
56. Sieber C, Kopf J, Hiepen C, Knaus P. (2009). Recent advances in BMP receptor signaling. Cytokine Growth Factor Rev 20: 343-355.
57. Stearns D, Chaudhry A, Abel TW, Burger PC, Dang CV, Eberhart CG. (2006). c-Myc overexpression causes anaplasia in medulloblastoma. Cancer Res 66: 673-681.
58. Sutter R, Shakhova O, Bhagat H, Behesti H, Sutter C, Penkar S et al. (2010). Cerebellar stem cells act as medulloblastoma-initiating cells in a mouse model and a neural stem cell signature characterizes a subset of human medulloblastomas. Oncogene 29: 1845-1856.
59. Thawani JP, Wang AC, Than KD, Lin CY, La Marca F, Park P. (2010). Bone morphogenetic proteins and cancer: review of the literature. Neurosurgery 66: 233-246; discussion 246.
60. Thompson MC, Fuller C, Hogg TL, Dalton J, Finkelstein D, Lau CC et al. (2006). Genomics identifies medulloblastoma subgroups that are enriched for specific genetic alterations. J Clin Oncol 24: 1924-1931.
61. Vita M, Henriksson M. (2006). The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16: 318-330.
62. von Bueren AO, Shalaby T, Rajtarova J, Stearns D, Eberhart CG, Helson L et al. (2007). Anti-proliferative activity of the quassinoid NBT-272 in childhood medulloblastoma cells. BMC Cancer 7: 19.
63. Walsh DW, Godson C, Brazil DP, Martin F. (2010). Extracellular BMP-antagonist regulation in development and disease: tied up in knots. Trends Cell Biol 20: 244-256.
64. Wu KJ, Grandori C, Amacker M, Simon-Vermot N, Polack A, Lingner J et al. (1999). Direct activation of TERT transcription by c-MYC. Nat Genet 21: 220-224.
65. Yabe T, Samuels I, Schwartz JP. (2002). Bone morphogenetic proteins BMP-6 and BMP-7 have differential effects on survival and neurite outgrowth of cerebellar granule cell neurons. J Neurosci Res 68: 161-168.
66. Yan W, Chen X. (2007). Targeted repression of bone morphogenetic protein 7, a novel target of the p53 family, triggers proliferative defect in p53-deficient breast cancer cells. Cancer Res 67: 9117-9124.
67. Yanagita M. (2005). BMP antagonists: their roles in development and involvement in pathophysiology. Cytokine Growth Factor Rev 16: 309-317.
68. Yanagita M. (2009). BMP modulators regulate the function of BMP during body patterning and disease progression. Biofactors 35: 113-119.
69. Ye L, Bokobza SM, Jiang WG. (2009). Bone morphogenetic proteins in development and progression of breast cancer and therapeutic potential (review). Int J Mol Med 24: 591-597.
70. Ye L, Lewis-Russell JM, Davies G, Sanders AJ, Kynaston H, Jiang WG. (2007). Hepatocyte growth factor up-regulates the expression of the bone morphogenetic protein (BMP) receptors, BMPR-IB and BMPR-II, in human prostate cancer cells. Int J Oncol 30: 521-529.
71. Yu PB, Hong CC, Sachidanandan C, Babitt JL, Deng DY, Hoyng SA et al. (2008). Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolism. Nat Chem Biol 4: 33-41.
72. Zeller KI, Zhao X, Lee CW, Chiu KP, Yao F, Yustein JT et al. (2006). Global mapping of c-Myc binding sites and target gene networks in human B cells. Proc Natl Acad Sci USA 103: 17834-17839.
73. Zhao H, Ayrault O, Zindy F, Kim JH, Roussel MF. (2008). Posttranscriptional down-regulation of Atoh1/Math1 by bone morphogenic proteins suppresses medulloblastoma development. Genes Dev 22: 722-727.